GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ningbo Menovo Pharmaceutical Co Ltd (SHSE:603538) » Definitions » Piotroski F-Score

Ningbo Menovo Pharmaceutical Co (SHSE:603538) Piotroski F-Score : 6 (As of Apr. 18, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Ningbo Menovo Pharmaceutical Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ningbo Menovo Pharmaceutical Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Ningbo Menovo Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

SHSE:603538' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 5   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Ningbo Menovo Pharmaceutical Co was 8. The lowest was 1. And the median was 5.


Ningbo Menovo Pharmaceutical Co Piotroski F-Score Historical Data

The historical data trend for Ningbo Menovo Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ningbo Menovo Pharmaceutical Co Piotroski F-Score Chart

Ningbo Menovo Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 5.00 5.00 2.00 -

Ningbo Menovo Pharmaceutical Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 1.00 4.00 6.00 -

Competitive Comparison of Ningbo Menovo Pharmaceutical Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Ningbo Menovo Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ningbo Menovo Pharmaceutical Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ningbo Menovo Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Ningbo Menovo Pharmaceutical Co's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was 14.043 + 4.899 + 44.308 + 3.556 = ¥67 Mil.
Cash Flow from Operations was -54.423 + 9.956 + 116.464 + 25.54 = ¥98 Mil.
Revenue was 262.766 + 345.113 + 341.199 + 423.776 = ¥1,373 Mil.
Gross Profit was 95.234 + 84.171 + 123.136 + 145.188 = ¥448 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was
(4423.516 + 4344.246 + 4536.569 + 4615.562 + 4651.221) / 5 = ¥4514.2228 Mil.
Total Assets at the begining of this year (Dec23) was ¥4,424 Mil.
Long-Term Debt & Capital Lease Obligation was ¥664 Mil.
Total Current Assets was ¥1,971 Mil.
Total Current Liabilities was ¥1,586 Mil.
Net Income was 43.449 + -12.595 + 23.684 + -42.953 = ¥12 Mil.

Revenue was 246.318 + 335.945 + 346.271 + 287.966 = ¥1,217 Mil.
Gross Profit was 77.236 + 99.438 + 124.915 + 73.973 = ¥376 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(4419.493 + 4427.481 + 4330.741 + 4651.847 + 4423.516) / 5 = ¥4450.6156 Mil.
Total Assets at the begining of last year (Dec22) was ¥4,419 Mil.
Long-Term Debt & Capital Lease Obligation was ¥760 Mil.
Total Current Assets was ¥1,759 Mil.
Total Current Liabilities was ¥1,378 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ningbo Menovo Pharmaceutical Co's current Net Income (TTM) was 67. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ningbo Menovo Pharmaceutical Co's current Cash Flow from Operations (TTM) was 98. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=66.806/4423.516
=0.01510247

ROA (Last Year)=Net Income/Total Assets (Dec22)
=11.585/4419.493
=0.00262134

Ningbo Menovo Pharmaceutical Co's return on assets of this year was 0.01510247. Ningbo Menovo Pharmaceutical Co's return on assets of last year was 0.00262134. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Ningbo Menovo Pharmaceutical Co's current Net Income (TTM) was 67. Ningbo Menovo Pharmaceutical Co's current Cash Flow from Operations (TTM) was 98. ==> 98 > 67 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=663.966/4514.2228
=0.14708313

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=759.65/4450.6156
=0.17068425

Ningbo Menovo Pharmaceutical Co's gearing of this year was 0.14708313. Ningbo Menovo Pharmaceutical Co's gearing of last year was 0.17068425. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=1971.456/1585.961
=1.24306714

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=1759.375/1378.267
=1.27651246

Ningbo Menovo Pharmaceutical Co's current ratio of this year was 1.24306714. Ningbo Menovo Pharmaceutical Co's current ratio of last year was 1.27651246. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Ningbo Menovo Pharmaceutical Co's number of shares in issue this year was 207.707. Ningbo Menovo Pharmaceutical Co's number of shares in issue last year was 297.558. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=447.729/1372.854
=0.32613009

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=375.562/1216.5
=0.30872339

Ningbo Menovo Pharmaceutical Co's gross margin of this year was 0.32613009. Ningbo Menovo Pharmaceutical Co's gross margin of last year was 0.30872339. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=1372.854/4423.516
=0.31035357

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=1216.5/4419.493
=0.27525782

Ningbo Menovo Pharmaceutical Co's asset turnover of this year was 0.31035357. Ningbo Menovo Pharmaceutical Co's asset turnover of last year was 0.27525782. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+1+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ningbo Menovo Pharmaceutical Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Ningbo Menovo Pharmaceutical Co  (SHSE:603538) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Ningbo Menovo Pharmaceutical Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Ningbo Menovo Pharmaceutical Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Ningbo Menovo Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.999,Yangfan Road, Room 1406, No.1, High-tech Zone, Ningbo, CHN, 315040
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
Executives
Xu Jian senior management
Cao Qian Director
Yao Fang Director
Ying Gao Feng Director
Sun Yan Director
Shi Jian Xiang Director
Wu Feng Yun Director
Tu Ying Director
Yao Cheng Zhi Director
Zheng Hui Lin Supervisors
Jiao Hua senior management

Ningbo Menovo Pharmaceutical Co Headlines

No Headlines